Nemaura Pharma Receives Funding to Develop Biologic Micropatch System

February 7, 2017

The investment will be used to advance Nemaura’s R&D programs, which include liquid vaccines that have been reformulated for administration through the skin using its micropatch drug delivery technology.

Nemaura Pharma, a biotech company based in the United Kingdom, has secured up to GBP 5 million (approximately USD 6.2 million based on an exchange rate of GBP 1 = USD 1.24) of funding from private investors to develop a hormone biologic using its micropatch solid-dose delivery platform. The investment will be used to advance Nemaura’s R&D programs, which include liquid vaccines that have been reformulated for administration through the skin using its micropatch drug delivery technology.

The micropatch works by depositing the drug under the outer layer of the skin using a metal needle that retracts completely following administration; this safety feature minimizes the risk of stick injuries. According to the company, the micropatch improves control of drug release and absorption, stability performance, and can partially or completely eliminate the cold storage requirements of biologic drugs such as vaccines.

 

Source: Nemaura Pharma